Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2 …
JCH Yang, LV Sequist, SL Geater, CM Tsai… - The lancet …, 2015 - thelancet.com
Background Most patients with non-small-cell lung cancer tumours that have EGFR
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2 …
JCH Yang, LV Sequist, SL Geater, CM Tsai… - The Lancet …, 2015 - Elsevier
Background Most patients with non-small-cell lung cancer tumours that have EGFR
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …
[PDF][PDF] Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX …
JCH Yang, LV Sequist, SL Geater, CM Tsai, TSK Mok… - 2015 - prensamedica.org
Background Most patients with non-small-cell lung cancer tumours that have EGFR
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2 …
JCH Yang, LV Sequist, SL Geater, CM Tsai… - Lancet …, 2015 - ntur.lib.ntu.edu.tw
Background Most patients with non-small-cell lung cancer tumours that have EGFR
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …
[引用][C] Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX …
JCH Yang, LV Sequist, SL Geater, CM Tsai… - The Lancet …, 2015 - cir.nii.ac.jp
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring
uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and …
uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and …
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2 …
JCH Yang, LV Sequist, SL Geater, CM Tsai… - The Lancet …, 2015 - infona.pl
Most patients with non-small-cell lung cancer tumours that have EGFR mutations have
deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21, or both (ie …
deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21, or both (ie …
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2 …
JCH Yang, LV Sequist, SL Geater… - The Lancet …, 2015 - pubmed.ncbi.nlm.nih.gov
Background Most patients with non-small-cell lung cancer tumours that have EGFR
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2 …
JC Yang, LV Sequist, SL Geater, CM Tsai… - The Lancet …, 2015 - europepmc.org
Background Most patients with non-small-cell lung cancer tumours that have EGFR
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …